Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

January 9, 2019January 9, 2019

Risk of Atrial Fibrillation Increases in Certain Ankylosing Spondylitis Patients, Study Finds

News

Ankylosing spondylitis (AS) patients younger than 40 and those treated with tumor necrosis factor inhibitors (TNFi) are at a higher risk of developing atrial fibrillation, a heart condition that ... Read more

June 6, 2018June 8, 2018

Hypertension, Depression More Common in Patients Than Others of Same Age and Sex, Study Reports

Just Published, News

Ankylosing spondylitis patients carry a significantly higher burden for several comorbidities — other diseases — than are found in people without this inflammatory disorder of the same age and ... Read more

May 30, 2018May 30, 2018

Humira of Benefit Over Long Term to Nonradiographic Axial Spondyloarthritis Patients, Study Reports

News

Long-term treatment with Abbvie‘s adalimumab, sold as Humira, led to sustained clinical remission accompanied by better physical abilities in patients with nonradiographic axial spondyloarthritis (nr-axSpA). “Clinical and MRI remission ... Read more

April 23, 2018April 23, 2018

Increase in Early Spondyloarthritis Activity Linked to Decline in Physical Quality of Life, Study Shows

News

An increase in disease activity during the early stages of axial spondyloarthritis (axSpA) is linked to a decline in physical health-related quality of life in patients over time, according ... Read more

March 7, 2018March 7, 2018

Cosentyx Leads to Long-Term Improvement in AS Patients, Phase 3 Trial Shows

News

Results from a Phase 3 clinical trial show that treatment with Cosentyx (secukinumab) led to fast, significant, and sustained symptom improvement in patients with active ankylosing spondylitis (AS). Improvements were ... Read more

February 7, 2018February 7, 2018

Researchers Identify Promising Biomarkers for AS Diagnosis, Prognosis

News

Two single variants in immune system-related genes may help predict ankylosing spondylitis with active disease response to therapy. The study “The Diagnostic and Prognostic Role of Interleukin 12B and ... Read more

January 24, 2018January 24, 2018

Early Disease Onset, Long Duration Increase Comorbidity Risk in Ankylosing Spondylitis, Study Suggests

News

Early disease onset and long disease duration may increase the risk of additional diseases in patients with ankylosing spondylitis, according to the results of a Swedish study. The study, ... Read more

January 17, 2018January 17, 2018

Endothelium Function in AS Improved with Methotrexate Alone or Combined with Anti-TNF Agents, Study Finds

News

Methotrexate alone or combined with therapies targeting the inflammatory tumor necrosis factor (TNF) may help improve the endothelium function – the thin membrane that lines the inside of the ... Read more

November 1, 2017November 1, 2017

Novartis to Present Promising 4-year Data of Cosentyx at International Conference

News

Novartis will present new four-year data from the MEASURE 1 study showing how Cosentyx (secukinumab) benefits patients with ankylosing spondylitis at the 2017 ACR/ARHP Annual Meeting in San Diego, ... Read more

September 1, 2017September 1, 2017

E.U. Approves Imraldi, a Humira Biosimilar, for Ankylosing Spondylitis, Other Inflammatory Diseases

News

The European Commission recently granted a marketing authorization for Imraldi, a biosimilar approved to treat the same inflammatory diseases — including ankylosing spondylitis — as Humira (adalimumab). Imraldi, developed by Samsung ... Read more

Pin It on Pinterest